Participated · Series B · Apr 2026

Sepion Technologies develops ultra-thin, drop-in polymer separator coatings and membrane technologies intended to replace legacy ceramic materials in lithium-ion batteries. Its coatings aim to enable higher energy density, faster charging, and improved durability without requiring changes to existing battery manufacturing lines. The company reports its products are currently being manufactured on commercial production lines to support customer qualification with leading global battery manufacturers. Sepion is supporting multiple concurrent qualification programs for electric vehicle, energy storage system, and consumer electronics applications. Led by CEO Peter Frischmann and based in Alameda, CA, the company plans to use recent funding to scale U.S.-based polymer production, expand product lines, and strengthen quality and operations.

Participated · Series B · Feb 2026

BreezeBio, formerly GenEdit, engineers polymer-based NanoGalaxy nanoparticles that deliver genetic payloads such as mRNA with cell-type precision across immune, cardiac, pulmonary and central nervous system tissues. The company has shifted from being solely a delivery-technology provider to building a therapeutic pipeline concentrated on autoimmune disease and oncology. Its lead candidate, BRZ-101, delivers autoantigen-encoding mRNA and tolerogenic co-factors to antigen-presenting cells to induce antigen-specific regulatory T cells and aims to restore immune tolerance in type 1 diabetes; the program is now entering IND-enabling studies after positive preclinical results in mice and non-human primates. BreezeBio is also extending NanoGalaxy with ligand conjugation to reach T cells and enable in vivo CAR-T therapies. Beyond internal programs, the firm maintains a multi-year collaboration and licensing agreement with Genentech that has already produced an initial milestone payment. The recent financing strengthens its balance sheet, allowing continued platform expansion and clinical advancement of its pipeline.

Participated · Series B · Aug 2025

Datumo develops tools to verify and evaluate the reliability and performance of large language models, helping prevent errors and ensure safety in regulated industries. Its platform can automatically generate test questions, build test sets, and run end-to-end evaluation and analysis of model behavior. The company also provides AI development services, including creating pretraining datasets (for example converting printed text to datasets via OCR). Datumo was founded in 2018 (originally named electStar) and is participating in a government-selected consortium to develop a domestic base AI model, where it handles AI data engineering. The company is expanding internationally into Japan and the U.S.; its strategy chief moved from Seoul to Silicon Valley to lead global expansion. Financially, Datumo has raised $15.5M in the reported Series B and says cumulative funding now totals about $25M.

Participated · Series B · Feb 2025

EnCharge is a semiconductor startup spun out from Princeton that builds analog memory chips and full‑stack AI accelerators aimed at running existing AI models at the edge (laptops, handsets, wearables). The company says its accelerators use about 20x less energy to run workloads compared with other chips on the market and has developed noise‑resilient analog designs and accompanying software. EnCharge expects to have its first chips on the market later this year and is working closely with TSMC to manufacture those devices. The startup focuses on inference rather than training and continues R&D with algorithms that could expand use cases. EnCharge has received non-dilutive support via grants from DARPA and the Department of Defense and counts strategic backers such as In-Q-Tel among its investors. The company is Santa Clara‑based and emerged from stealth in 2022 after nearly a decade of research at Princeton. EnCharge AI commercializes next-generation in-memory computing chips and full-stack AI accelerators that use switched-capacitor analog techniques to deliver large improvements in compute efficiency and density. The company says its technology targets decentralizing AI inference from data centers to phones, laptops, vehicles, and factories. EnCharge was launched in 2022 and is led by co-founder and CEO Dr. Naveen Verma, with Dr. Kailash Gopalakrishnan as CTO. Headquartered in Santa Clara, Calif., the company is building on years of Princeton lab work and prior DoD/DARPA-funded research. Financially, EnCharge has raised $45 million to date and recently announced a $22.6 million funding round to develop next-generation full-stack AI compute solutions. It is also participating with Princeton University in a DARPA OPTIMA-supported multi-year project funded by an $18.6 million grant. EnCharge AI builds custom plug-in hardware on a standard PCIe form factor that uses in-memory computing to accelerate AI workloads for servers and network edge machines. The company’s chips are designed around capacitors rather than transistors to improve robustness against voltage and temperature fluctuations. EnCharge is developing accompanying software to enable customers to adapt different neural networks to the custom hardware and to keep the solution scalable. The firm emerged from research and DARPA- and federally funded R&D that Verma led beginning in 2017 and commercializes those test chips and architectures. EnCharge has roughly 25 employees, is based in Santa Clara, and is pre-revenue. Proceeds from the recent raise will be used for hardware and software development and to support new customer engagements.

Participated · Series B · May 2024

Elegen develops cell-free, microfluidics-based DNA synthesis and production technologies and markets the ENFINIA DNA product line for research and clinical workflows. The platform emphasizes longer, more complex, and faster DNA synthesis compared with traditional cell-based cloning, aiming to reduce synthesis failures, contamination, and hands-on time. Elegen commercialized ENFINIA DNA in Q1 2023, introduced higher-scale synthesis options in early Q4 2023, and in March launched a service for rapid synthesis of highly complex sequences. The company is focused on providing turnkey production of GMP-compliant DNA to support discovery and clinical development of genetic medicines. Recent plans supported by the financing include development of IVT-ready DNA, plasmid DNA and clinical-grade DNA production across clinical manufacturing workflows. Elegen also has a strategic collaboration with GSK to apply its cell-free DNA manufacturing technology to vaccines and medicines.